These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28913908)

  • 1. Provision of cellular blood components to CMV-seronegative patients undergoing allogeneic stem cell transplantation in the UK: survey of UK transplant centres.
    Morton S; Peniket A; Malladi R; Murphy MF
    Transfus Med; 2017 Dec; 27(6):444-450. PubMed ID: 28913908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfusion in CMV seronegative T-depleted allogeneic stem cell transplant recipients with CMV-unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: a U.K. dual centre experience.
    Hall S; Danby R; Osman H; Peniket A; Rocha V; Craddock C; Murphy M; Chaganti S
    Transfus Med; 2015 Dec; 25(6):418-23. PubMed ID: 26114211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfusion of CMV-unselected blood components may lead to inappropriate donor selection for patients subsequently undergoing allogeneic stem cell transplant.
    Morton S; Danby R; Rocha V; Peniket A; Murphy MF
    Transfus Med; 2015 Dec; 25(6):411-3. PubMed ID: 26914496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.
    Narvios AB; Przepiorka D; Tarrand J; Chan KW; Champlin R; Lichtiger B
    Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation.
    Ljungman P; Brand R; Hoek J; de la Camara R; Cordonnier C; Einsele H; Styczynski J; Ward KN; Cesaro S;
    Clin Infect Dis; 2014 Aug; 59(4):473-81. PubMed ID: 24850801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study.
    Narvios AB; Lichtiger B
    Haematologica; 2001 Jul; 86(7):749-52. PubMed ID: 11454531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME).
    Thiele T; Krüger W; Zimmermann K; Ittermann T; Wessel A; Steinmetz I; Dölken G; Greinacher A
    Transfusion; 2011 Dec; 51(12):2620-6. PubMed ID: 21645009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT.
    Schmidt-Hieber M; Tridello G; Ljungman P; Mikulska M; Knelange N; Blaise D; Socié G; Volin L; Blijlevens N; Fegueux N; Yakoub-Agha I; Forcade E; Maertens J; Chevallier P; Passweg J; Cornelissen J; Russell N; Craddock C; Bourhis JH; Marchand T; Reményi P; Cahn JY; Michallet M; Montoto S; Kröger N; Glaß B; Styczynski J
    Ann Hematol; 2019 Jul; 98(7):1755-1763. PubMed ID: 30993417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of cytomegalovirus serostatus on outcome of hematopoietic stem cell transplantation.
    Ljungman P
    Curr Opin Hematol; 2014 Nov; 21(6):466-9. PubMed ID: 25159712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of human cytomegalovirus-seronegative donor/-seropositive recipient high-risk combination frequency in allogeneic hematopoietic stem cell transplantations at Institute of Hematology and Blood Transfusion during 1995-2014.
    Nemeckova S; Sroller V; Stastna-Markova M
    Transpl Infect Dis; 2016 Apr; 18(2):297-301. PubMed ID: 26858009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients.
    Johnson RJ; Clatworthy MR; Birch R; Hammad A; Bradley JA
    Transplantation; 2009 Jul; 88(1):77-82. PubMed ID: 19584684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk of transfusion-acquired CMV infection in seronegative solid-organ transplant recipients receiving non-WBC-reduced blood components not screened for CMV antibody (1984 to 1996): experience at a single Canadian center.
    Preiksaitis JK; Sandhu J; Strautman M
    Transfusion; 2002 Apr; 42(4):396-402. PubMed ID: 12076284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation.
    Camargo JF; Komanduri KV
    Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):233-238. PubMed ID: 28641094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survey of current practice for prevention of transfusion-transmitted cytomegalovirus in the United States: leucoreduction vs. cytomegalovirus-seronegative.
    Smith D; Lu Q; Yuan S; Goldfinger D; Fernando LP; Ziman A
    Vox Sang; 2010 Jan; 98(1):29-36. PubMed ID: 19695013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
    Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
    Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfusion of leukoreduced cellular blood components from cytomegalovirus-unscreened donors in allogeneic hematopoietic transplant recipients: analysis of 72 recipients.
    Narvios AB; de Lima M; Shah H; Lichtiger B
    Bone Marrow Transplant; 2005 Sep; 36(6):499-501. PubMed ID: 16044143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of donor factors other than serologic status on transmission of cytomegalovirus to transplant recipients.
    Chou SW; Norman DJ
    Transplantation; 1988 Jul; 46(1):89-93. PubMed ID: 2839917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients.
    Pergam SA; Xie H; Sandhu R; Pollack M; Smith J; Stevens-Ayers T; Ilieva V; Kimball LE; Huang ML; Hayes TS; Corey L; Boeckh MJ
    Biol Blood Marrow Transplant; 2012 Sep; 18(9):1391-1400. PubMed ID: 22387334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of transfusion-transmitted cytomegalovirus infection.
    Pamphilon DH; Rider JR; Barbara JA; Williamson LM
    Transfus Med; 1999 Jun; 9(2):115-23. PubMed ID: 10354380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of a cytomegalovirus serology dual-testing strategy in hematopoietic stem cell transplant recipients.
    Perry DA; Hakki M
    Transpl Infect Dis; 2016 Oct; 18(5):809-814. PubMed ID: 27502917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.